Visiox Pharma, LLC

Santen Pharmaceutical Co., Ltd. has filed for global first approval of sepetaprost (study code: STN1012600), its dual agonist of the FP and EP3 receptors, for glaucoma in Japan. The filing, announced

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Teams With Oblique On Antibody Di

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Astellas To Select Up To Five Targ

Nicox S.A. posted mostly favorable Phase III data from the first of two pivotal trials for its glaucoma/ocular hypertension eye drop NCX 470, but missed demonstrating superiority versus a comparator